BioNxt Solutions Inc.

BNXT

CA0909741062

Pharmaceuticals

Delayed Canadian Securities Exchange Other stock markets 09:43:58 2024-05-23 EDT			5-day change	1st Jan Change
0.38 ^CAD	-2.56%		-5.00%	-21.65%

04-26	BioNxt Solutions Inc. Announces ODF Cladribine Update	CI
04-26	BioNxt Solutions Inc. announced that it expects to receive CAD 1.62 million in funding	CI

XPhyto Therapeutics Corp. Appoints Per S. Thoresen to the Board of Directors

November 04, 2020 at 06:01 pm

XPhyto Therapeutics Corp. announce the appointment of Mr. Per S. Thoresen to the Company's board of directors effective immediately.

Latest news about BioNxt Solutions Inc.

BioNxt Solutions Inc. Announces ODF Cladribine Update	04-25	CI
BioNxt Solutions Inc. announced that it expects to receive CAD 1.62 million in funding	04-25	CI
BioNxt Solutions Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-22	CI
BioNxt Solutions Provides Update on Commercialization of ODF Cladribine Product for Multiple Sclerosis	03-18	MT
BioNxt Solutions Inc. Reports Commercialization of Odf Cladribine Product for MS Next Steps	03-18	CI
BioNxt Solutions Reported Results From ODF Cladribine PK Study	03-13	MT
BioNxt Solutions Inc. Reports Successful Results from ODF Cladribine PK Study	03-13	CI
BioNxt Solutions Reports Completion of ODF Cladribine PK Study	03-04	MT
BioNxt Solutions Inc. Reports Successful Results from Odf Cladribine Toxicity Study	02-07	CI
BioNxt Solutions Inc. announced that it has received CAD 1.168 million in funding	01-28	CI
BioNxt Solutions Completed Cladribine ODF Toxicity Study and Financing	12-22	MT
BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing	12-21	CI
BioNxt Solutions Inc. announced that it expects to receive CAD 2.4 million in funding	12-20	CI
BioNxt Solutions Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-23	CI
BioNxt Solutions Inc Reports on New Cladrabine Odf Product Development and Commercialization Program	11-15	CI
BioNxt Solutions Inc. announced that it has received CAD 2.00075 million in funding	23-10-26	CI
BioNxt Solutions Inc. Announces Change of Directors	23-10-03	CI
BioNxt Solutions Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-27	CI
BioNxt Solutions Inc. announced that it expects to receive CAD 3.975 million in funding	23-08-04	CI
BioNxt Solutions Inc. Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease	23-08-02	CI
BioNxt Solutions Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
Bionxt Solutions Inc. Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson's Disease	23-05-15	CI
BioNxt Completes Pilot Study for Contract Development Customer	23-05-09	MT
BioNxt Secures Contract to Develop and Manufacture ODF Product for International Pharmaceutical Co	23-04-24	MT
BioNxt Acquires Equipment For European Commercial Manufacturing Capacity, Updates Enteric Coating Drug Delivery Program	23-04-17	MT

BioNxt Solutions Inc. is a bioscience company. The Company is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany. The Company is also focused on regulatory approval and commercialization of medical products for European markets. The Company, through its subsidiary, 3a-diagnostics GmbH, offers diagnostic products, which include COVID-19 PCR Diagnostic Kit and Peri-Implantitis Oral Biosensor.

Sector

Pharmaceuticals

Calendar

2024-05-27 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BIONXT SOLUTIONS INC.	-21.65%	31.24M
ELI LILLY AND COMPANY	+39.59%	723B
NOVO NORDISK A/S	+34.28%	595B
JOHNSON & JOHNSON	-4.04%	369B
MERCK & CO., INC.	+20.29%	332B
ABBVIE INC.	+2.85%	282B
ASTRAZENECA PLC	+17.02%	244B
NOVARTIS AG	+9.31%	208B
ROCHE HOLDING AG	-5.07%	205B
PFIZER, INC.	-0.35%	168B

Other Pharmaceuticals

BioNxt Solutions Inc.

Equities

BNXT

CA0909741062

Pharmaceuticals

XPhyto Therapeutics Corp. Appoints Per S. Thoresen to the Board of Directors

Latest news about BioNxt Solutions Inc.

Chart BioNxt Solutions Inc.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals